Freenome (United States)

InstitutionResearch output, impact & collaborations

Freenome (United States) is a institution indexed in ScholarIQ from OpenAlex.

What is known about Freenome (United States)?

ScholarIQrecord summary

Freenome (United States) is a research organisation in South San Francisco, United States. OpenAlex records 278 works and 17,840 citations for it. 1 researchers list it as their most recent affiliation.

How many works does Freenome (United States) have?

ScholarIQindexed works

Freenome (United States) has 278 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

See the works listed for Freenome (United States) →

How many citations does Freenome (United States) have?

ScholarIQcitation count

Freenome (United States) has 17,840 citations in the OpenAlex counts ScholarIQ stores.

See the listed works for Freenome (United States) →

How many researchers are at Freenome (United States)?

ScholarIQresearcher count

Freenome (United States) has 1 researchers in the ScholarIQ index.

See the researchers listed on this page →

What is the average h-index at Freenome (United States)?

ScholarIQavg h-index

Freenome (United States) has an average h-index of 39 in OpenAlex.

Open the OpenAlex record →

What is the ROR of Freenome (United States)?

ScholarIQror

The ROR for Freenome (United States) is on the source record.

Open the ROR →

What is the OpenAlex record for Freenome (United States)?

ScholarIQopenalex

The OpenAlex for Freenome (United States) is on the source record.

Open the OpenAlex →

Who are the most-cited researchers behind Freenome (United States)?

ScholarIQtop researchers by citations

Richard Bourgon · Cancer Genomics and Diagnostics

172 works25,268 citations

What are the most-cited papers on Freenome (United States)?

ScholarIQmost cited works

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, José Luis Perez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer

The Lancet. 20163,735 Citations

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

Charles M. Rudin, Steffen Durinck, Eric Stawiski, John T. Poirier, Zora Modrušan, David S. Shames, Emily Anne Smith Bergbower, Yinghui Guan, James Shin, Joseph Guillory, Celina Sanchez Rivers, Catherine K. Foo, Deepali Bhatt, Jeremy Stinson, Florian Gnad, Peter M. Haverty, Robert Gentleman, Subhra Chaudhuri, Vasantharajan Janakiraman, Bijay S. Jaiswal, Chaitali Parikh, Wenlin Yuan, Zemin Zhang, Hartmut Koeppen, Thomas D. Wu, Howard M. Stern, Robert L. Yauch, Kenneth E. Huffman, Diego D’Ávila Paskulin, Peter B. Illei, Marileila Varella‐Garcia, Adi F. Gazdar, Frédéric J. de Sauvage, Richard Bourgon, John D. Minna, Malcolm V. Brock, Somasekar Seshagiri

Nature Genetics. 20121,105 Citations

How much of the research on Freenome (United States) is open access?

ScholarIQopen access share

0%OPEN ACCESS

Gold

Green

Hybrid

Bronze

Closed

100%